Dublin, Ireland, 18 May 2023 - Recently, MicroPort NeuroTech™ (Shanghai) Co., Ltd., (hereinafter referred to as "MicroPort NeuroTech™"), completed the first clinical implantation of NUMEN™ Detachable Embolization Coil (hereinafter referred to as "NUMEN™ coil") at Beaumont Hospital in Ireland, in which the surgical team gave positive feedback on the clinical performance of the NUMEN™ coil.
The first two cases of aneurysm embolization surgery were successfully completed by Dr. Alan O'Hare and his team. The first patient was diagnosed with a ruptured anterior communicating artery aneurysm with a daughter sac. The treatment method used by the surgeon was balloon-assisted coil embolization, which successfully achieved occlusion of the aneurysm. The NUMEN™ coil, with its stable formation, clear imaging, and dense embolization during the surgery, left a positive impression on the surgical team.
The second surgery was for an unruptured saccular aneurysm in the C7 segment of the internal carotid artery, with a maximum diameter of 12mm. The surgical team placed a total of 10 NUMEN™ coils, and the surgery was highly successful. During the procedure, the good pushability of the NUMEN™ coil, and the excellent performance of the NumenFR™ coil detachment (hereinafter referred to as "NumenFR™") in achieving detachment in one attempt, were highly praised by the medical team.
NUMEN™ coils are categorized in three series with a total of 177 specifications, including MicroFrame, MicroFill, and MicroFinish. They offer excellent conformability which leads to adherent scaffolding and dense packing, and allow doctors to choose the most suitable size for accurate occlusion during surgery. The extremely fine platinum tungsten wire material and unique three-dimensional structure of NUMEN™ coils allow for both softness and conformability, minimizing pressure on the aneurysm wall. They are suitable for the treatment of aneurysms of different shapes and provide a comprehensive embolization treatment plan for intracranial aneurysm surgery.
The successful completion of the first clinical implantation of NUMEN™ coils in Ireland will further promote the product's accelerated entry into the European market. In the future, MicroPort NeuroTech™ will continue to strengthen its cooperation with clinical experts at home and abroad and is committed to providing better solutions for global patients with cerebrovascular diseases.
About MicroPort NeuroTech™
Founded in Shanghai in 2012, MicroPort NeuroTech Limited (“MicroPort NeuroTech™”), a subsidiary of MicroPort Scientific Corporation (“MicroPort®”, stock code: 00853.HK), is committed to the research and development of high-end medical devices in the field of neurological interventional treatment. Currently, our solutions support 134 cerebrovascular stenting procedures every day. In the future, MicroPort NeuroTech™ will invest more resources in innovation and development to provide more high-quality and innovative cerebrovascular and neuro intervention solutions for doctors and patients.
More information is available at www.medneurotech.com.